A patient with type 2 diabetes has been managing his blood glucose levels using diet and metformin (Glucophage). Following an ordered increase in the patient's daily dose of metformin, the nurse should prioritize which of the following assessments?

Choice A reason: Neutrophil levels are not typically affected by metformin. Metformin does not have a high association with bone marrow suppression or agranulocytosis. These assessments would be more appropriate for medications like clozapine or certain chemotherapy agents, rather than biguanide anti-diabetic medications used for glucose management. Choice B reason: Metformin is actually more commonly associated with gastrointestinal side effects like diarrhea and abdominal cramping, especially when the dose is increased. Constipation is not a standard side effect of the medication. While GI assessments are important for comfort, they do not represent the primary physiological safety concern for metformin therapy. Choice C reason: While severe hypoglycemia can alter the level of consciousness, metformin does not typically cause hypoglycemia when used as monotherapy because it does not stimulate insulin secretion. Therefore, behavior and consciousness monitoring are less critical than in patients taking sulfonylureas or insulin. Choice D reason: Metformin is primarily excreted unchanged by the kidneys. If renal function is impaired (indicated by high creatinine and BUN), metformin can accumulate in the body, significantly increasing the risk of lactic acidosis—a rare but potentially fatal metabolic complication. Assessing renal function is essential, especially when increasing the dosage of this medication.